![Actinomycosis mimicking malignancy](https://sbmt.org.br/wp-content/uploads/2024/07/img-05.jpg)
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
14/10/2021
**Esta reportagem reflete exclusivamente a opinião do entrevistado.**